Skip to main content
Stock Expert AI
Biotech Brief INTERMEDIATE ✨ AI Enhanced

Humira's heirs now dwarf Humira. AbbVie's debt is the catch.

5 min read Data as of 6 sources
ABBV$286.20+0.94%Today, Nov 22, 2026: 84/100

AI-generated editorial content. For informational purposes only. Not financial advice.

The Take

  • Handoff, mostly done. Skyrizi sold $5.78B last quarter, far more than the $683.0M from Humira.
  • Debt remains. FMP lists net debt of $70.13B, and shareholders' equity is negative.
  • Next up. AbbVie presents at a Piper Sandler conference on Dec. 2; its next report is due Feb. 3, 2027.
  • 286.2 USDShare priceAs of
  • 0.94%Day changeAs of
  • 10.3%Revenue vs a year ago
  • 83MoonshotScoreAs of
Generic Drug Research (5956) (8493712946)

Stock Expert AI data cover: figures from Financial Modeling Prep. Photo: The U.S. Food and Drug Administration / Public domain

Humira's replacements now outsell Humira by a wide margin at AbbVie (ABBV): Skyrizi brought in $5.78B in the third quarter, against $683.0M for Humira. Both figures are for the quarter ended Sept. 30, 2026.

That is the point of this theme: a drugmaker whose best-selling product can lose its protection has to replace that income fast. AbbVie's results show how far along it is.

The idea

Big drug companies live on a few blockbuster medicines. When a blockbuster's patents run out, cheaper copies can arrive, and sales of the original usually shrink. Investors call this a patent cliff. The question is whether newer drugs grow fast enough to fill the gap.

The pattern to look for is simple. The old product falls, the new products rise, and total revenue keeps growing anyway.

The example

AbbVie's old blockbuster is Humira, an immunology drug. In the third quarter ended Sept. 30, 2026, Humira revenue was $683.0M, lower than the $993.0M of a year earlier. The figures show the fall, not its cause.

Its two successors in immunology both grew. Skyrizi revenue was $5.78B, up from $4.71B a year earlier. Rinvoq revenue was $2.71B, up from $2.18B.

Total revenue was $17.40B, up 10.3% from the year-ago quarter. According to FMP, that was $88.3M above the analyst estimate of $17.32B. Diluted earnings per share were $2.38. Separately, the EPS figure FMP compares with analyst estimates, $3.82, beat the $3.73 estimate; it is not the diluted EPS.

The company's margins also moved. Its operating margin was 36.0% in the latest quarter, against 12.1% in the year-ago quarter, which was an unusually low base. The margin also slipped slightly from the prior quarter. Free cash flow was $7.30B in the quarter.

In its Nov. 20, 2026 release, AbbVie said it will take part in the Piper Sandler Annual Healthcare Conference on Dec. 2, 2026, with a fireside chat that investors can follow by webcast.

The stock traded at 286.2 USD on the latest quote (Nov. 20, 2026), up 0.94% on the day. That is 5.5% below its 52-week high of 302.93 USD.

AbbVie's MoonshotScore is 83 (Exceptional). Its strongest section is momentum at 90 and its weakest is valuation at 49.

Risks

  • Debt. FMP reports net debt of $70.13B as of Sept. 30, 2026, and shareholders' equity of -$4.58B. Its Altman Z score, a bankruptcy-risk gauge, is 2.63.
  • Price. The trailing price-to-earnings ratio, which compares the share price with profit per share, is 49.09. Amgen (AMGN) has a P/E of 25.07 and Bristol-Myers Squibb (BMY) has a P/E of 13.01. FMP's discounted cash flow model value is 127.85 USD per share, well below the share price; that is a model estimate, not our view.
  • Concentration. Two drugs now carry a large share of sales, so any slowdown in Skyrizi or Rinvoq would matter more than a Humira decline.
  • Insiders. Among recent filings in the last 90 days, FMP shows one insider sale and no open-market purchases.

What to watch next

  • Dec. 2, 2026: the Piper Sandler fireside chat, where management can update investors.
  • Feb. 3, 2027: the next earnings report. FMP shows an EPS estimate of 3.88 and a revenue estimate of $18.35B. That date is 75 days after the Nov. 20 quote.
  • Skyrizi and Rinvoq revenue in that report, against Humira's decline.

Key facts

  • Oct. 30, 2026: AbbVie reported EPS of 3.82 against an estimate of 3.73, and revenue of $17.40B against an estimate of $17.32B.
  • Sept. 30, 2026: cash and short-term investments were $10.77B and total debt was $80.90B.
  • Third quarter FY2026: dividends paid were $3.07B, and free cash flow was $7.30B.
  • Analyst consensus (FMP): average price target 316.87 USD, with a range of 275.00 USD to 349.00 USD. Of 44 ratings, 31 are buy, 12 are hold and 1 is sell.
  • Trailing 12 months: dividend yield of 2.4% and a net margin of 15.7%.
MetricLatest (Q3 FY2026)Year-ago (Q3 FY2025)
Revenue$17.40B$15.78B
Skyrizi$5.78B$4.71B
Rinvoq$2.71B$2.18B
Humira$683.0M$993.0M
Operating income$6.27B$1.90B

Frequently asked questions

Q: Is Skyrizi bigger than Humira at AbbVie now?

Yes. In the third quarter ended Sept. 30, 2026, Skyrizi revenue was $5.78B and Humira revenue was $683.0M. Rinvoq, at $2.71B, was also larger than Humira.

Q: How much debt does AbbVie carry?

FMP lists total debt of $80.90B and net debt of $70.13B as of Sept. 30, 2026. Shareholders' equity was -$4.58B. The company also had cash and short-term investments of $10.77B.

Q: When does AbbVie report next?

FMP shows the next earnings date as Feb. 3, 2027, with an EPS estimate of 3.88 and a revenue estimate of $18.35B. Before that, management speaks at the Piper Sandler conference on Dec. 2, 2026.

This is educational content, not investment advice. Past performance does not guarantee future results.

What to watch next

  1. The Piper Sandler fireside chat, where management can update investors.
  2. The next earnings report. FMP shows an EPS estimate of 3.88 and a revenue estimate of $18.35B. That date is 75 days after the Nov. 20 quote.

ABBV on Stock Expert AI

MoonshotScore 84/100 Nov 22, 2026

A 0-100 score built from five sections.

  • Quality83
  • Safety75
  • Valuation48
  • Growth72
  • Momentum92
🎯

MoonshotScore AI Ratings

Each stock is scored 0-100 on five pillars: Business Quality, Financial Safety, Valuation, Growth Durability and Momentum. A story quotes the score of the day it was written.

ABBV Today, Nov 22, 2026: 84/100When published, Nov 22, 2026: 83/100

Related Tickers

earningsbiotechnology

Sources

Related Sectors & Industries

Next story

Momentum Movers Why did Gap stock rise? Outlets point to a profit beat 3 min readGAP
👁 Editorial Transparency
🧠Content generated by AI editorial engine
👤Stock Expert AI Research is an AI editorial voice of Stock Expert AI
✅Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
🛡Financial Modeling Prep (FMP)
🕑Last updated:

Get the week's earnings in one Thursday email

The S&P 500 companies on that week's earnings calendar, each with its current MoonshotScore, plus the week's Journal research. Free, one email a week, with an unsubscribe link in every issue.

We send one confirmation email first and nothing else until you click its link (it works for 7 days). After that, the Weekly only. Your address is not sold or shared. Newsletter details · Free guide: How to read a MoonshotScore · Privacy Policy


Explore More Market Intelligence

Evidence & Sources

  • Figures come from Financial Modeling Prep (FMP). SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.
  • MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). Weights are rescaled to 100 when all five pillars have data: 28.3%, 21.7%, 19.6%, 17.4% and 13.0% of the score. It reads no news-sentiment or analyst data, and it is not a probability of future returns.
  • Definitions follow standard investing terminology, with key terms explained inline in plain language where useful.
  • Each price is the last quote we recorded, shown with the trading session it belongs to. Pages are served from a cache, so the copy you are reading can lag that quote. Each quote is a provider snapshot, not an exchange feed.
  • This page is educational and does not constitute investment advice.
  • Numbers come from market data providers (FMP); AI writes the plain-English explanations around them, which should be verified with independent research.